The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Statins and hepatotoxicity: Focus on patients with fatty liver†
Open accessAbstract
Statins are among the most widely prescribed medications in the western world.1 Their benefit in the primary and secondary prevention of cardiovascular disease is unequivocal. The results from clinical trials have shown that statins decrease the mortality from coronary artery disease and decrease the incidence of myocardial infarction, revascularization procedures, stroke and peripheral vascular disease.2 Currently, six statins are available for clinical use including lovastatin which is available in a generic form in the United States. These medications are widely prescribed and more than 10 million prescriptions were written in the United States in the year 2003 alone3 (Table 1). Numerous clinical trials and extensive clinical experience have established that currently available statins have an excellent safety profile. Although clinically significant liver injury is extremely rare from statins, asymptomatic elevations in liver enzymes are common in patients who are placed on statins. Because of this phenomenon and due to the information contained within the package inserts, potential hepatotoxicity from statins has become a source of concern for physicians who prescribe them. In clinical practice, gastroenterologists and hepatologists are often asked to see patients who developed liver enzyme elevations after prescribing statins and also about the safety of prescribing statins in hyperlipidemic individuals with asymptomatic liver enzyme elevations. This article discusses various aspects of statin hepatotoxicity including the safety of statins in patients with nonalcoholic fatty liver disease (NAFLD) and the merits of current product labeling (Table 2). The issue of using statins in patients with known or suspected fatty liver disease is particularly relevant as statins are now available without a prescription in some parts of the world (United Kingdom) and thus a large number of individuals with undiagnosed fatty liver disease may consume statins without their knowledge. ALT, Alanine Aminotransferase; ULN, upper limit of normal; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis. Initial toxicology studies in animals suggested that statins may cause significant liver problems. Although the usual doses of lovastatin did not cause significant liver injury, when given in very high doses they caused hepatocellular necrosis in rabbits.4 Similarly, high doses of simvastatin caused hepatocellular necrosis in guinea pigs.5 The liver injury in these animals could be prevented or reversed with supplementing animals with mevalonate suggesting that depletion of mevalonate or its downstream metabolite might be responsible for liver injury.4, 5 However, it does not appear that statins cause hepatocellular necrosis in a predictable fashion in humans. The most common clinical hepatic manifestation of statins is asymptomatic elevation in aminotransferases and this appears to be a class effect of statins.2, 6-8 The clinical trials that evaluated the efficacy of statins have arbitrarily but consistently used persistent and significant elevation in alanine aminotransferase levels (>3 times upper limit of normal [ULN] on two or more measurements) as a safety end point. The incidence of this abnormality with different statins is less than 3% and there is a minor dose-related increase in its incidence2, 7 (Table 3). Very rarely, after initiating statins, the liver enzymes can rise to significantly higher levels with no evidence of liver dysfunction. For example, in the prospective pravastatin pooling project (PPP project), 0.5% of the patients who received 40 mg of pravastatin had ALT greater than 5 times ULN and 0.2% had ALT greater than 9 times ULN.9 In general, the incidence of liver enzyme elevations in the statin treated patients has not been consistently different than in the placebo-treated patients.9, 10 In a recent meta-analysis that consisted of 49,275 patients who participated in 13 large, placebo-controlled trials of statins, therapy with statins at low-to-moderate doses was not associated with a significant increase in liver enzyme elevations compared to placebo (OR 1.26, 95% CI 0.99-1.62).10 This comparable incidence of liver enzyme elevation between statin and placebo-treated patients raises the possibility that hyperlipidemic patients may have spontaneous fluctuations in transaminases whether or not they receive statins.9-12 In patients who exhibit elevated aminotransferases, the liver enzymes decrease upon stopping or reducing the dose.6 However, the natural history of elevated aminotransferases if the statins are continued at the same doses is not well known. There is a suggestion that such patients may exhibit "adaptation" and their aminotransferases remain stable or trend downwards even when statins are continued.6 Although several reports of significant liver injury associated with statins have appeared in the literature, it appears to be very rare.8, 13-16 Statins do not appear to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M., & Liddle, C. (1998) · Hepatology · doi:10.1002/hep.510270121 · Cited by 614
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Hamelin, B. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01147-4 · Cited by 468
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Self-citationLiver transplantation for acute liver failure from drug induced liver injury in the United States
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. (2004) · Liver Transplantation · doi:10.1002/lt.20204 · Cited by 393
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Fatty Infiltration of Liver in Hyperlipidemic Patients
Assy, N., Kaita, K., Mymin, D., Levy, C., Rosser, B., & Minuk, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005661516165 · Cited by 360
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Chalasani, N., Deeg, M. A., & Crabb, D. W. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30159.x · Cited by 343
Self-citationShould there be a moratorium on the use of cholesterol lowering drugs?
Davey Smith, G., & Pekkanen, J. (1992) · BMJ · doi:10.1136/bmj.304.6824.431 · Cited by 333
Strandberg, T. E., Pyörälä, K., Cook, T. J., Wilhelmsen, L., Faergeman, O., Thorgeirsson, G., Pedersen, T. R., & Kjekshus, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 331
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 220
Chitturi, S., & George, J. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30102 · Cited by 216
Tolman, K. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02355-x · Cited by 214
Preclinical evaluation of lovastatin
MacDonald, J. S., Gerson, R. J., Kornbrust, D. J., Kloss, M. W., Prahalada, S., Berry, P. H., Alberts, A. W., & Bokelman, D. L. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90003-3 · Cited by 199
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 195
Potential antitumor effects of statins (Review)
Jakobisiak, M., & Golab, J. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.4.1055 · Cited by 193
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre-Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
Rallidis, L. S., Drakoulis, C. K., & Parasi, A. S. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.008 · Cited by 181
Autoimmune Hepatitis Triggered by Statins
Alla, V., Abraham, J. P., Siddiqui, J., Raina, D., Wu, G. Y., Chalasani, N., & Bonkovsky, H. L. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200609000-00018 · Cited by 137
Self-citationVuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200502000-00002 · Cited by 133
Self-citationBottorff, M. B., & Hansten, P. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2273 · Cited by 124
Use and Monitoring of "Statin" Lipid-Lowering Drugs Compared With Guidelines
Abookire, S. A., Karson, A. S., Fiskio, J. M., & Bates, D. W. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.1.53 · Cited by 115
Screening for Statin-Related Toxicity
Smith, C. C., Bernstein, L. I., Davis, R. B., Rind, D. M., & Shmerling, R. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.688 · Cited by 110
Chalasani, N., Gorski, J. C., Patel, N. H., Hall, S. D., & Galinsky, R. E. (2001) · Hepatology · doi:10.1053/jhep.2001.29306 · Cited by 98
Self-citationDefining patient risks from expanded preventive therapies
Tolman, K. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00946-2 · Cited by 98
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis
Graziadei, I., Obermoser, G., Sepp, N. T., Erhart, K. H., & Vogel, W. (2003) · Lupus · doi:10.1191/0961203303lu313cr · Cited by 97
Hepatotoxicity of hypolipidemic drugs
Parra, J. L., & Reddy, K. R. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00024-2 · Cited by 93
Autoimmune hepatitis revealed by atorvastatin
Pelli, N., Setti, M., Ceppa, P., Toncini, C., & Indiveri, F. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200308000-00014 · Cited by 89
Liver disease in patients with diabetes mellitus
Foster, K. J., Griffith, A. H., Dewbury, K. C., Price, C. P., & Wright, R. (1980) · Postgraduate Medical Journal · doi:10.1136/pgmj.56.661.767 · Cited by 62
Atorvastatin for the treatment of NASH
HORTANDER, J., Kwo, P. Y., Cummings, O. W., et al. (2001) · Gastroenterology · doi:10.1016/s0016-5085(08)82704-7 · Cited by 54
Horsmans, Y., Desager, J. P., & Harvengt, C. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00840.x · Cited by 49
Fatal liver failure with atorvastatin
Perger, L., Kohler, M., Fattinger, K. E., Flury, R., Meier, P. J., & Pauli‐Magnus, C. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00464-1 · Cited by 46
Eidelman, R. S., Lamas, G. A., & Hennekens, C. H. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2033 · Cited by 45
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Statins and cancer: a case of meta-uncertainty
Güallar, E., & Goodman, S. N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00758-6 · Cited by 14
The liver and statin drug therapy: uncertain navigation in the sea of risk‐benefit
Caldwell, S. H., Zaidman, J. S., & Hespenheide, E. E. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.833 · Cited by 12
Research works printed but not linked: 4
- Kemmer, 2001, High prevalence of NASH among Mexican American females with type II diabetes mellitus, Gastroenterology, 120, A117, 10.1016/S0016-5085(01)80576-X · doi:10.1016/s0016-5085(01)80576-x
- Burdick, 2004, Insulin related endothelial dysfunction in patients with nonalcoholic fatty liver disease (NAFLD), HEPATOLOGY, 40, 589A
- Lersch, 2004, Treatment of HCC with pravastatin, octreotide, or gemcitabine‐critical evaluation, Hepatogastroenterology, 51, 1099
- Shek, 2001, Statin‐fibrate combination therapy, Ann Pharmacother, 35, 908, 10.1345/aph.10315 · doi:10.1345/aph.10315 · Paper page
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Metadata
- Authors
- Chalasani, N.
- Venue
- Hepatology
- Published
- 2005-04
- Volume
- 41
- Issue
- 4
- Pages
- 690-695
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2089003251
- Cited by
- 265
- References
- 43
- FWCI
- 16.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3805 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.